Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02649686
Title Durvalumab in Patients With HER-2 Positive Metastatic Breast Cancer Receiving Trastuzumab
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Canadian Cancer Trials Group

Her2-receptor positive breast cancer


Durvalumab + Trastuzumab

Age Groups: adult
Covered Countries CAN

No variant requirements are available.